CBX

 Chia Tai-Tianqing (CTTQ) has initiated a clinical study ( NCT06218771 ) of TQB3454, an IDH1 inhibitor, in patients with AML/MDS. This trial started in July 2023, while the study of IDH2 inhibitor TQB3455 was terminated in 2021 due to slow enrollment . IDH mutations for cancer The first Investigational New Drug (IND) application for TQB3454 was filed for the treatment of solid tumors and blood cancers in China in 2020. The first-in-human clinical trial was initiated in August of that year enrolling patients with advanced solid tumors or hematologic malignancies. While no results from this initial trial have been publicly reported, several other clinical trials for TQB3454 are currently ongoing and recruiting participants. In 2023, CTTQ initiated a phase 1 clinical study ( NCT05987358 ) of TQB3454 in patients with  advanced biliary carcinoma , with an estimated enrollment of 165 participants. IDH1 mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma. A